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Abstract 49 
Intraperitoneal vancomycin is the first line therapy in the management of peritoneal dialysis-related 50 
peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on 51 
automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. 52 
Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide 53 
guidelines for dosing and are often extrapolated for APD use, but it is unclear if this is appropriate.  This 54 
review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on 55 
CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically 56 
summarized, knowledge gaps explored, and a vancomycin dosing algorithm in peritoneal dialysis 57 
patients is proposed. 58 
 59 
 60 
 61 
 62 
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 65 
 66 
 67 
 68 
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INTRODUCTION 73 
Vancomycin is often selected as empiric first line therapy for suspected Gram-positive organisms 74 
in peritoneal dialysis (PD) related peritonitis. However, data on vancomycin dosing in various PD 75 
modalities are limited, especially for automated peritoneal dialysis (APD). The paucity of well-designed 76 
pharmacokinetic studies has led to vancomycin dosing guidelines for PD patients that are based on 77 
limited information resulting in the possibility of achieving sub-or supra-therapeutic trough 78 
concentrations in this special patient population.(1) 79 
 80 
PRINCIPLES OF VANCOMYCIN THERAPY 81 
Vancomycin is a tricyclic glycopeptide antibiotic with broad spectrum activity against Gram-82 
positive bacteria. It is effective for the treatment of Gram-positive infections including peritonitis and is 83 
the drug of choice for methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is poorly 84 
absorbed following oral administration. Therefore, it is commonly administered as an intravenous 85 
infusion, except in peritoneal dialysis where the route is preferentially intraperitoneal. Approximately 86 
50% of vancomycin is protein-bound in plasma with a variable volume of distribution ranging between 87 
0.4-1 L/kg in the non-PD population.(2, 3) An initial distribution half-life ranging from 30 minutes to 1 88 
hour followed by a mean terminal elimination half-life ranging from 6-12 hours were determined 89 
following intravenous dosing in patients with normal renal function.(3) Metabolism is negligible and 90 
elimination occurs primarily through glomerular filtration, such that advanced renal disease substantially 91 
reduces the clearance of vancomycin resulting in an elimination half-life of about 7.5 days compared to 92 
4-6 hours in normal patients. This means that in patients with kidney failure, the dosing of vancomycin 93 
must be adjusted.(4, 5)  94 
The Clinical and Laboratory Standards Institute (CLSI) has established the vancomycin 95 
breakpoint for susceptible S. aureus isolates with MIC values of < 2 mg/L and intermediate or resistant 96 
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for MIC values greater than 2 mg/L.(6) Despite the CLSI defined breakpoints, treatment failure for 97 
patients infected with S. aureus and vancomycin MICs between 1-2 mg/L have been reported compared 98 
to those with lower reported MICs.(7, 8) This may be due to inappropriate selection of doses that are 99 
sufficiently high to maintain plasma concentrations that exceed the MIC. 100 
To optimize the vancomycin exposure-response relationship for efficacy during S. aureus 101 
infections, one must examine the ratio of the area under the concentration-time curve and the MIC 102 
(AUC/MIC). Vancomycin trough concentrations between 15-20 mg/L for MIC breakpoints < 1 mg/L 103 
ensures a ratio of > 400 and has been an advocated target for clinical effectiveness.(3, 9) It should be 104 
noted that goal trough values recommended by consensus guidelines for efficacy may lead to 105 
nephrotoxicity, which might be a consideration for patients on PD with residual kidney function.(10) This 106 
however, is not well studied. In practice, clinical judgement together with therapeutic drug monitoring 107 
(TDM) of steady-state vancomycin plasma concentrations is a common approach in the treatment of 108 
peritonitis in PD.  109 
 110 
PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION 111 
Pharmacokinetic/pharmacodynamic modeling and simulation is an innovative approach that can 112 
help inform crucial decisions, such as predicting clinical endpoints of new doses and dosing regimens or 113 
optimization of drug regimens. By understanding what the body does to the drug (Pharmacokinetics) 114 
and what the drug does to the body (Pharmacodynamics), dosing regimens can be tailored to the PD 115 
population to avoid nephrotoxicity, retain antimicrobial eradication and suppressing the emergence of 116 
resistance. Regulatory authorities mandate the submission of pharmacokinetic/pharmacodynamic 117 
evaluations for drug application, which include dose evaluation in special populations. However, despite 118 
the evaluation of the need of dose adjustments for patients with end stage renal disease (ESRD) - such 119 
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as those on hemodialysis- the process is not well established for old drugs. Even in those cases when 120 
dose adjustments are proposed for patients with ESRD, there is minimal attention in patients on PD.  121 
This review aims to summarize the available evidence on vancomycin pharmacokinetic and 122 
pharmacodynamic PD-related studies, address the physicochemical and PD modality-specific 123 
considerations- with attention on APD, and highlight areas where research is needed on dosing 124 
vancomycin for PD-related peritonitis.  125 
 126 
VANCOMYCIN PHYSICOCHEMICAL PROPERTIES AND DRUG TRANSPORT ACROSS THE PERITONEUM  127 
Movement of vancomycin from the peritoneum cavity to plasma is based on Fick’s Law (figure 128 
1). Middle molecular weight solutes such as vancomycin (1,486 g/mol) are dependent on dwell time 129 
during PD for absorption into the plasma. Based upon a single dose study of six non-infected subjects on 130 
PD, vancomycin has a lower dialysate to plasma ratio than urea and creatinine at two hours.(11)  There 131 
is no correlation between vancomycin PD clearance and dialysis adequacy (Kt/V) following an 132 
intravenous dose in patients on APD.(12)  133 
Teicoplanin, a glycopeptide antibiotic with a similar molecular structure (1,564 g/mol) and 134 
spectrum of activity to vancomycin, was studied in non-infected adults on continuous ambulatory 135 
peritoneal dialysis (CAPD).(13) The absolute bioavailability (Fip) was calculated using dialysate drug 136 
concentration (corrected for amount remaining in the cavity) and drug amount sampled, which was then 137 
plotted against a total dwell time of five hours. Teicoplanin systemic bioavailability, reflecting transfer 138 
from the peritoneal space, was directly related to dwell time. Furthermore, the consistency in 139 
absorption increased with time suggesting that complete and less variable bioavailability with 140 
teicoplanin can be achieved with longer dwell times.  141 
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The rate at which vancomycin is absorbed is dependent on the permeability of the peritoneal 142 
membrane. Vancomycin intraperitoneal to systemic transfer rate increases in patients with 143 
inflammatory peritonitis.(14)  144 
 145 
VANCOMYCIN BIOAVAILABILITY DURING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 146 
Vancomycin pharmacokinetics has primarily been studied in patients on CAPD. Bioavailability 147 
studies conducted in these patients typically employ a 6-hour dwell time. The Fip, or the amount of 148 
vancomycin reaching systemic circulation from the peritoneal space relative to an intravenous dose, is 149 
approximately 50%.(15) Supporting the hypothesis of a leaky peritoneum due to membrane 150 
inflammation, patients on CAPD with peritonitis have a Fip of 70-91%.(14, 16) Bioavailability changes can 151 
also be observed with different age cohorts. For example, in a pediatric study in children aged 5-17 years 152 
old, the bioavailability was reported to be as high as about 70% in the absence of peritonitis.(17)  153 
      A summary of the absorption parameters from studies conducted in infected and non-infected 154 
patients on CAPD is depicted in table 1. The equilibration half-life describes the time allowed for drug 155 
transfer between the peritoneal space to the systemic circulation following an intraperitoneal dose of 156 
vancomycin. Following intraperitoneal dosing, vancomycin equilibration half-life in patients on CAPD 157 
without peritonitis was 2.9 hours and those with peritonitis 1.6-2.9 hours.(18-20) Assuming no 158 
differences between peritoneum transport in those with or without peritonitis and five half-lives, 159 
steady-state equilibrium between the dialytic compartment and systemic circulation would be achieved 160 
following a 10-15 hour dwell.  161 
 162 
VANCOMYCIN BIOAVAILABILITY DURING AUTOMATED PERITONEAL DIALYSIS  163 
Vancomycin possess the desired physiochemical properties as a drug candidate for 164 
intraperitoneal administration in APD patients. In addition, with its well-established stability in PD fluids, 165 
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bioavailability is adequate as long as sufficient dwelling time is allowed for drug absorption. However, 166 
the appropriate duration of the dwell time has not been well studied. Hence, it is crucial to monitor 167 
vancomycin levels frequently to adjust dosing to get therapeutic concentrations in each individual 168 
patient.  169 
 170 
VANCOMYCIN CLEARANCE DURING PERITONEAL DIALYSIS  171 
Vancomycin elimination following an intraperitoneal dose is governed by its total body 172 
clearance. Total body clearance is the sum of clearances contributed from elimination organs, mainly 173 
kidneys, in the case of vancomycin, and is defined as the volume of plasma cleared of vancomycin per 174 
time unit. Elimination processes in PD patients include those originating from residual kidney function 175 
(RKF), other non-renal sources plus the drug cleared through PD. Total body clearance is especially 176 
important as it controls the overall exposure of vancomycin for the given bioavailability achieved from a 177 
dwell. Dialytic clearance is defined as the volume of plasma that has been cleared of vancomycin (i.e. 178 
removed from systemic circulation into the peritoneal space) by PD per unit time. Figure 1 describes the 179 
various clearance processes involved in vancomycin elimination following an intraperitoneal dose. 180 
Moreover, a summary of vancomycin pharmacokinetic systemic parameters is provided in table 2. 181 
Vancomycin clearance in patients on PD differs among studies due to several factors including the 182 
presence or absence of peritonitis, presence and extent of RKF, dwell times, dialysate volume, effect of 183 
antibiotic-free PD exchanges, and age.(21)  184 
 185 
CONTINUOUS AMBULATORY PERITONEAL DIALYSIS   186 
Continuous ambulatory peritoneal dialysis typically employs short dwell times (4-6 hours), which 187 
may not be sufficient to reach equilibration between the dialysate and plasma. Studies in non-infected 188 
adult CAPD patients report dialytic clearances ranging between 1.2-2.4 mL/min, which account for 20-189 
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25% of the total plasma clearance.(15, 22, 23) In patients with peritonitis, vancomycin dialytic clearance 190 
increases to 3.8 mL/min following a less-than five-hour exchange.(24) Clearances of up to 8.5 mL/min 191 
after the first 4 hours of exchange have also been reported.(16) Vancomycin clearance through 192 
elimination from the drained peritoneal dialysate contributes to 20-70% of the total plasma 193 
clearance.(16, 24) As a consequence, vancomycin elimination half-life in the systemic circulation ranges 194 
between 66–115 hours in patients on CAPD.(22, 24-26) One major reason in the reported variability in 195 
the plasma half-life could be the difference in the sampling times which may not completely capture the 196 
decline of the plasma concentrations during the terminal elimination phase. Table 2 also includes a 197 
summary of above parameters in these patients.  198 
 199 
AUTOMATED PERITONEAL DIALYSIS  200 
Studies conducted in the APD population are only reserved to the parenteral administration of 201 
antibiotics in patients without peritonitis, yet vancomycin is primarily used to treat peritonitis and is 202 
mostly administered intraperitoneally.(27, 28) With rapid cycling, the dialytic clearance of vancomycin 203 
may be increased. Therefore, if doses and dwell times used for those on the cycler are similar to those in 204 
CAPD, the result may be sub-therapeutic levels due to frequent exchanges.  205 
To date, there has only been one study exploring intravenous vancomycin disposition in subjects 206 
on APD.(12) The primary objective was to characterize vancomycin pharmacokinetic parameters in 207 
adults without peritonitis after a single intravenous dose. Following the intravenous administration of 15 208 
mg/kg, subjects received three cycle treatments over the course of eight hours followed by two 8-hour 209 
off-cycler dwells for a total of 24 hours. A 2-liter 2.5% dextrose dialysate prescription was used during 210 
and off-cycler dwell. The plasma half-life was 11.6 hours following an on-cycler exchange consisting of 211 
three 2-hour dwells. When the same patients were removed from the cycler and allowed to dwell for 7-212 
8 hours, the plasma half-life increased to 62.8 hours. Although vancomycin was not dosed 213 
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intraperitoneally in this study, rapid decline in the plasma half-life support the contribution of APD in the 214 
removal of drug. Clearance values did not largely differ from those on CAPD. Approximately 30% of 215 
vancomycin was removed by APD relative to the total plasma clearance, which is close to the proportion 216 
reported in patients on CAPD. Although intraperitoneal vancomycin administration is recommended by 217 
guidelines in patients with PD peritonitis, this intravenous administration study provides a valuable 218 
insight towards drug clearance during APD.(29) It should be noted that intravenous administration of 219 
vancomycin may not be adequate to achieve effective antibacterial concentrations in the 220 
peritoneum.(30)  221 
The current International Society for Peritoneal Dialysis (ISPD) guideline recommends 222 
supplemental dosing in order to achieve plasma vancomycin troughs above 15 mg/L when administered 223 
intermittently. Alternatively, temporarily switching to CAPD is another option for APD patients who 224 
develop peritonitis, but is not always feasible.  In patients on APD, leveraging the long dwell to 225 
appreciate optimal vancomycin transfer is appropriate to ensure adequate time to achieve and sustain 226 
therapeutic levels.  227 
 228 
IMPACT OF RESIDUAL KIDNEY FUNCTION (RKF) AND TREATMENT OUTCOME 229 
Residual kidney function in PD patients will have a profound effect for hydrophilic drugs 230 
removed exclusively through renal filtration. Enhanced drug clearance from RKF may have implications 231 
to treatment outcomes in patients with PD-related peritonitis. Therefore, patients with greater RKF may 232 
require higher or more frequent antibiotic dosing. 233 
The importance of RKF on the outcome of PD-related peritonitis in patients treated with 234 
antibiotics has been discussed for more than ten years, but the data describing this relationship are still 235 
scarce and controversial. The ISPD 2010 update on PD-related infections has previously recommended a 236 
25% increase in antibiotic dose in patients with a daily urine output of over 100 mL.(31) This 237 
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recommendation has been removed in the updated 2016 guideline, which reflects the lack of evidence 238 
to support this empiric recommendation.(29) In a retrospective study examining the impact of RKF on 239 
vancomycin concentrations, the influence of RKF was found to not have a significant impact.(32) 240 
Vancomycin concentrations appeared lower in patients who were non-anuric across both modalities 241 
even though a 25% higher dose was administered to those with RKF. This however was concluded to not 242 
be statistically significant. Similar results have been published showing no difference in treatment 243 
outcomes in non-anuric and anuric patients treated with cefazolin and gentamicin.(33)    244 
In contrast, a recent study investigating the relationship between RKF and PD-related peritonitis 245 
treatment outcomes was able to explain treatment failures related to the remaining degree of renal 246 
function.(34) Treatment failure in those with Gram-positive and culture-negative peritonitis were found 247 
to be significantly higher for patients with a urinary creatinine clearance greater than 0-5 mL/min 248 
compared to those who were anuric. Significantly higher relapse and recurrence were observed in those 249 
patients with Gram-positive or culture-negative infections and creatinine clearances greater than 5 250 
mL/min. Cefazolin and vancomycin were the main antibiotics used in the study. These observations may 251 
be useful when attempting to understand the impact of RKF on treatment outcomes and raise the 252 
question as to whether patients with RKF greater than 5 mL/min were under-dosed with antibiotic in 253 
previous studies.  254 
In patients treated with vancomycin, RKF may account for 10-23% of the total body clearance in 255 
PD.(12, 22) Studies examining the impact of RKF on vancomycin clearance, exposure, and treatment 256 
outcomes in PD-related peritonitis are limited. Interestingly, for the subset of patients with a glomerular 257 
filtration rate greater than 5 mL/min, RKF accounted for 39-84% of the total vancomycin clearance.(12) 258 
It would appear that the impact from RKF has a substantial effect on the total clearance of vancomycin. 259 
Thus, the recent 2016 ISPD recommendation of removing the 25% dosage increase to account for RKF is 260 
unclear as most of the studies cited accounted for a dosage increase for those who were non-anuric.(32, 261 
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35) In the absence of additional studies, dosage adjustments to account for RKF may still be appropriate 262 
as there is a substantial contribution observed on the total vancomycin clearance.  For now, we can only 263 
speculate that the resulting impact in treatment failure for Gram-positive peritonitis may be associated 264 
with higher drug clearance values in patients with creatinine clearances greater than 5 mL/min.  265 
 266 
THERAPEUTIC DRUG MONITORING AND PHARMACODYNAMIC RESPONSE  267 
Vancomycin therapeutic drug monitoring is critical for patients with peritonitis and is routinely 268 
performed because 1) the concentration plays the key component for the effect and 2) the initial 269 
antibiotic dose is needed to target the maximum effect in order to allow proper eradication and 270 
prevention of resistance. Moreover, the treatment window timeframe is crucial for patients. Hence, 271 
appropriate plasma sampling during this timeframe is important, but may be difficult as the turnaround 272 
time for assay results is a rate-limiting factor in achieving desired therapeutic drug levels. Furthermore, 273 
not only is it important to ensure that the initial dose is sufficient, but also if that initial dose is able to 274 
maintain therapeutic effect throughout treatment. Yet, current clinical practice is based on empirical 275 
decisions, which may not reflect the most optimized regimen for patients on PD. 276 
The traditional role of plasma trough concentration monitoring has been conflicting in the PD 277 
population. Unlike the established optimal plasma trough levels of 10-15 mg/L for uncomplicated 278 
infections or 15-20 mg/L for complicated infections, there is substantial interpatient variability for those 279 
patients on PD.  Higher rates of PD-related peritonitis relapse have been associated with a cumulative 4-280 
week plasma trough below 12 mg/L when compared to those maintained above that threshold.(36) In 281 
this study, vancomycin was given intravenously where plasma levels were maintained above 12 mg/L 282 
rather than the current 15 mg/L recommendation by the ISPD. The type of modality did not differ 283 
among the outcome groups, however vancomycin clearance and RKF information were not reported 284 
which may have contributed to variability in the plasma concentration. On the other hand, data from a 285 
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single-center study involving 34 PD patients experiencing PD-related peritonitis showed no relationship 286 
between plasma vancomycin levels measured during the first week and PD-related peritonitis 287 
outcomes.(37) Here, CAPD was reportedly the most frequent modality (80%) used with an average 288 
residual creatinine clearance of 2.8 mL/min/1.73m2. Vancomycin was dosed based on ISPD 289 
recommendations and plasma levels were maintained above 15 mg/L. Of these 34 PD patients with 290 
confirmed Gram-positive infections, 43% of cases were associated with coagulase-negative 291 
Staphylococcus ssp. while only 11% of cases were due to MRSA. In total, although the frequency and 292 
level of vancomycin measurement was not associated with adverse clinical events during the first week 293 
of treatment, the number of patients studied may be too small to draw a firm conclusion. 294 
Pharmacokinetic sources of variability can be explained in part due to varying exchanges provided by the 295 
patient’s PD modality, impact from RKF, and peritoneum physiology affecting drug absorption. In 296 
addition, the pharmacodynamics- or bacterial susceptibility measured by its MIC- contributes to the 297 
variability in clinical response, which may not be explained due to vancomycin pharmacokinetics alone.  298 
Taken together, vancomycin shows substantial interindividual variability in clinical response for 299 
patients treated for PD-related peritonitis. Table 3 gives an overview of the 300 
pharmacokinetic/pharmacodynamic factors to be considered at the time of TDM of vancomycin in 301 
patients on both CAPD and APD regimens.  302 
 303 
CONSIDERATIONS FOR INTRAPERITONEAL DOSING   304 
Clinicians should consider dwell times that achieve substantial equilibrium between the 305 
peritoneum compartment and the systemic circulation. The reported bioavailabilities in literature are 306 
dwell-time specific and may not be applicable in all patient-specific situations. Therefore, considering 307 
the transfer half-life between the dialytic compartment and systemic circulation can be useful to 308 
understand the time that it takes to reach equilibrium (i.e., steady-state). This may take up to 15 hours 309 
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considering a transfer half-life of 3 hours.(19) In this situation, dosing during the long-dwell interval may 310 
provide adequate drug absorption to achieve therapeutic concentrations in plasma in patients on APD.  311 
The bioavailability of vancomycin significantly increases during PD-related peritonitis. Plasma 312 
concentrations as high as 40 mg/L have been reported following a 6 hour dwell using recommended 313 
intraperitoneal doses of vancomycin in PD-related peritonitis.(14, 16) Alternatively, plasma 314 
concentrations as low as 10 mg/L have been reported following a 6 hour dwell using a 500 mg 315 
intraperitoneal dose in PD-related peritonitis.(38) Regardless of the PD modality, absorption does not 316 
largely change between CAPD or APD based on the equilibration half-lives reported.(12, 19, 20)  317 
In patients with PD peritonitis on APD, doses of 15-20 mg/kg together with dwell times ranging 318 
from 10-15 hours may be more appropriate than the targeted concentration strategy mentioned above. 319 
TDM should also be performed to evaluate therapeutic and toxic concentration fluctuations and to 320 
maintain concentrations above 15 mg/L as recommended by the ISPD guidelines.  321 
 322 
FUTURE RESEARCH AND DOSING GUIDELINES IN AUTOMATED PERITONEAL DIALYSIS 323 
Empiric Gram-positive management using vancomycin for PD-related peritonitis in patients on 324 
APD is summarized in figure 2. This algorithm accounts for RKF and suggests a dosage increase of 20% 325 
for those who are non-anuric with a creatinine clearance greater than 5 mL/min based on observational 326 
outcome studies.(34) In addition, monitoring plasma vancomycin concentrations 48 hours post-dose 327 
would be appropriate based on previous experience. As such, re-dosing would be necessary to maintain 328 
the targeted 15 mg/L concentration. During this time, adjustments to antibiotic therapy should be 329 
guided by the microbiology or susceptibility report. This should be practiced together with routine TDM 330 
at appropriate sampling times to rationally select the effective dose for each patient. Pharmacometric 331 
modeling and simulation could help to increase the knowledge on vancomycin dose exposure response 332 
relationship and propose optimal dosing and TDM strategies in PD patients.  333 
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As above recommendations are based on limited evidence, dedicated studies are needed to 334 
support them. Table 4 highlights the knowledge gaps and propose future research topics to better tailor 335 
vancomycin treatments in PD patients with peritonitis. 336 
 337 
CONCLUSION 338 
Optimal dosing for vancomycin should consider both the pharmacokinetic (concentration in 339 
dialysis fluid and plasma), RKF, PD modality, and physicochemical factors (bioavailability, permeability) 340 
and pharmacodynamics (MIC and variability to the susceptibilities of the organism). Generally, 341 
vancomycin is given intraperitoneally during the long day dwell for patients on APD; this approach 342 
supports adequate equilibration during the absorption phase between dialysate and plasma to reach 343 
therapeutic levels. In addition, the impact of rapid cycling and RKF on the total body clearance has yet to 344 
be fully defined. With this in mind, TDM may be appropriate, however, there is yet to be an established 345 
protocol in PD patients with peritonitis.  As the option to temporarily switch to CAPD in APD patients 346 
who develop peritonitis may not be convenient, the need for future research on the impact of the cycler 347 
on vancomycin clearance is imperative. Upcoming studies (NCT03685747) examining the 348 
pharmacokinetic of vancomycin will address some of the knowledge gaps associated with vancomycin 349 
pharmacokinetic in patients on APD. For the moment, clinicians should consider the bioavailability, 350 
dwell time, and institutional microbiological susceptibilities when dosing vancomycin in PD. Dedicated 351 
pharmacokinetic studies in adult and pediatric patients are needed to understand vancomycin 352 
disposition in PD patients on rapid-cycling modalities. The integrated use of TDM and MICs via dosing 353 
algorithms may help improve clinical outcome.   354 
 355 
 356 
 357 
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Table 1. Vancomycin absorption parameters in adult and pediatric non-infected and PD-related peritonitis patients on peritoneal dialysis.  504 
Adults 
Infection 
Status 
Dose 
Dwell Time 
(hours) 
Bioavailability (%) Dosing 
Plasma Concentration 
Reference 
 (mg/L) 
Time of 
sampling (hour) 
Negative 
30 mg/kg 6 49 Single 24.9 6 [15] 
10 mg/kg 4 65 Single 6.3 5 [25] 
PD-
Peritonitis 
30 mg/kg 6 91 Single 40 4 [14] 
2 g 6 70 Single 39.7 6 [16] 
500 mg 6 83 Multiple 10.2 6 [38] 
15 mg/kg 4 66 Single 16.1 6 [19] 
30 mg/kg 10-12 N/A Multiple 33.8 12 [39] 
Pediatric 
Infection Dose Dwell Time Bioavailability (%) Dosing 
Plasma Concentration 
Reference 
(mg/L) 
Time of 
sampling 
Negative 550 mg/m2 6 70 Single 23.3 6 [17] 
N/A = not reported 505 
(39) 506 
 507 
 508 
 509 
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Table 2. Vancomycin distribution and clearance parameters in adult and pediatric non-infected and PD-related peritonitis patients on CAPD or 510 
APD. 511 
Adults 
Modality  Infection Status Route Vd (L/kg) 
Plasma Half-
life (hours)  
Clearance (mL/min) 
Reference 
Total Dialytic  Renal 
CAPD 
Negative 
 
IP 0.56 111 5 1.2 N/A [15] 
IV 0.73 92 6.4 1.4 0.65 [22] 
PD-Peritonitis 
IP 0.61 N/A N/A 15.7 N/A [19] 
IP 0.87 N/A 8.5 12.2 N/A [20] 
IV 0.55 104 4.1 3.8 N/A [24] 
IV 1.1 115 7.2 1.4 N/A [26] 
APD Negative IV 0.4 11.6 / 62.8a 7.4 2.1 1.7 [12] 
Pediatric 
Modality  Infection Route Vd (L/kg) Plasma   
Clearance (mL/min/1.73m2) 
Reference 
Total Dialytic  Renal 
CAPD 
Negative IP 0.48 25 
10.7 2.5 
1.4 [17] 
APD 14.9 3.1 
aHalf-life during the ambulatory CAPD portion of the study. APD = automated peritoneal dialysis, CAPD = continuous ambulatory peritoneal dialysis, 512 
N/A = not reported, Vd = volume of distribution 513 
 514 
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Table 3. Pharmacokinetic/pharmacodynamic factors for TDM consideration between CAPD and APD vancomycin regimens.  515 
Pharmacokinetic/pharmacodynamics PD components CAPD APD 
Absorption 
Dwell time ↓ Bioavailability ↑ Bioavailability 
Dosing route (IP vs. IV) Same 
Distribution 
Permeability (Peritonitis vs. 
non-peritonitis) 
Same 
Diffusion 
Protein binding 
Surface area 
Vascularity 
Elimination 
Dosing route (IP vs. IV) RKF- Drives variation in systemic circulation 
Body size & Dialysate volume Same- Patient dependent  
Dwell time ↑ Clearance ↓ Clearance 
Number of non-antibiotic 
exchanges ↓ Clearance ↑ Clearance 
Pharmacodynamics MIC/AUC Same- Susceptibility report 
APD = Automated peritoneal dialysis, AUC = area under the vancomycin plasma-concentration time curve, CAPD = continuous ambulatory 516 
peritoneal dialysis, IP = intraperitoneal, IV = intravenous, MIC = minimal inhibitor concentration, PD = peritoneal dialysis, RKF = residual kidney 517 
function 518 
 519 
 520 
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Table 4. Proposal for critical research areas to optimize vancomycin therapy in peritoneal dialysis. 521 
Proposal for Critical Research Areas of Needed Research for Vancomycin Therapy in Peritoneal Dialysis 
▪ Effect of APD on peritoneal and plasma levels during rapid cycles 
▪ Peak concentration following absorption from the long-dwell 
▪ Optimal trough concentrations associated with improved clinical outcomes and the timing of trough monitoring specific for the 
peritoneal dialysis population 
▪ Dosing regimen to achieve optimal trough concentrations 
▪ Effect of residual kidney function on vancomycin disposition and its implications on dosing 
▪ Factors affecting non-renal and non-dialytic clearance of vancomycin  
▪ Determining appropriate clinical plasma sampling time points 
APD = Automated Peritoneal Dialysis   522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
23 
 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
Figure 1. Illustration of vancomycin absorption, distribution and elimination following an intraperitoneal dose. 541 
Increasing the dwell time enhances vancomycin bioavailability. Peritoneum and dialysate properties should be considered as these both affect the 542 
rate and extent of absorption following an intraperitoneal dose. Following dosing and an appreciable dwell time, vancomycin is eliminated by PD, 543 
renal, and non-renal sources. These processes make up the total body clearance of vancomycin.   544 
This illustration is a derivative of “Simple squamous epithelium”, “Arteries”, “Arterial circulation” and “Bubble” by Servier Medical Art 545 
(https://smart.servier.com/) under the Creative Commons License (CC BY 3.0).   546 
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 557 
 558 
Figure 2. Proposed vancomycin dosing and monitoring algorithm in patients on automated peritoneal dialysis. 559 
Vancomycin dosing in patients on APD with peritonitis should follow the recommended 15-20 mg/kg dose administered intraperitoneally. For 560 
those who are non-anuric with creatinine clearances > 5 mL/min, a 20% increase in the calculated dose is suggested. A vancomycin level should 561 
be obtained 48 hours post-dose. Dosage adjustments and monitoring should be based on clinical response and microbiological susceptibility 562 
reports.  563 
